A 25 Percent Shift: Redefining Health Interventions A 25 percent average body weight reduction. That stark figure, emerging from late-stage clinical trial data for the new obesity drug, retatrutide, demands more than just medical headlines; it forces Read More
Beyond the Headlines: A Single Dose, A Multi-Decade Question The immediate euphoria surrounding VERVE-102’s interim Phase I results—a staggering 62 percent reduction in LDL cholesterol—misses the most critical elephant in the biotech lab. Read More